Kanada - angielski - Health Canada

glenmark pharmaceuticals canada inc. - ursodiol - tablet - 250mg - ursodiol 250mg - cholelitholytic agents

Kanada - angielski - Health Canada

glenmark pharmaceuticals canada inc. - ursodiol - tablet - 500mg - ursodiol 500mg - cholelitholytic agents

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

avkare - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin is contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia ( see warnings and precautions ). - known hypersensitivity to metformin. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function ( see

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - mesalazine - gastro-resistant tablet - 800mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - modified-release tablet - 75mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - modified-release tablet - 150mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - modified-release tablet - 150mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - modified-release tablet - 75mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies ( 14.1)]. bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets (xl) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

remedyrepack inc. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder (mdd).   efficacy of venlafaxine in mdd was shown in both short-term trials and a longer-term trial in mdd [ see clinical studies ( 14.1) ].   a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attemp